This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KRTX Karuna Therapeutics (KRTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisInsider TradesTrendsBuy This Stock About Karuna Therapeutics Stock (NASDAQ:KRTX) Get Karuna Therapeutics alerts:Sign Up Key Stats Today's Range$329.83▼$329.8350-Day Range$313.97▼$329.8352-Week Range$158.38▼$329.99VolumeN/AAverage Volume832,048 shsMarket Capitalization$12.58 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Read More Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRTX Stock News HeadlinesKaruna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s PsychosisAugust 12, 2025 | tipranks.comKaruna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s PsychosisJuly 17, 2025 | tipranks.comTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in modern history - larger than Paul Tudor Jones' Black Monday bet and Michael Burry's $700 million Big Short. While most investors chase AI stocks, insiders including Ray Dalio and Tudor Jones have quietly repositioned. The last comparable shock sent certain stocks up 2,464%, 2,778%, and even 13,000% - turning a $10,000 stake into over $1.3 million. Dr. Eifrig has identified one stock at the center of this story and released a free broadcast to help investors act before the window closes.August 2 at 1:00 AM | Stansberry Research (Ad)Karuna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s PsychosisJuly 4, 2025 | tipranks.comKaruna Therapeutics Advances Alzheimer’s Psychosis Treatment with KarXT StudyJune 27, 2025 | tipranks.comThis FDA-approved drug promises a new way to treat schizophreniaSeptember 30, 2024 | msn.comBMS wins approval for schizophrenia drug acquired from KarunaSeptember 27, 2024 | msn.comBristol Myers to Purchase KarunaSeptember 13, 2024 | msn.comSee More Headlines KRTX Stock Analysis - Frequently Asked Questions How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) announced its quarterly earnings results on Thursday, February, 22nd. The company reported ($3.01) earnings per share for the quarter, missing the consensus estimate of ($2.65) by $0.36. The firm's quarterly revenue was down 100.0% on a year-over-year basis. When did Karuna Therapeutics IPO? Karuna Therapeutics (KRTX) raised $70 million in an initial public offering (IPO) on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karuna Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Palo Alto Networks (PANW), Salesforce (CRM) and Netflix (NFLX). Company Calendar Last Earnings2/22/2024Today8/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:KRTX CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees339Year Founded2009Profitability EPS (Trailing Twelve Months)($11.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$433.68 million Net MarginsN/A Pretax Margin-66,209.48% Return on Equity-31.63% Return on Assets-30.38% Debt Debt-to-Equity RatioN/A Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual Sales$654 thousand Price / Sales19,239.07 Cash FlowN/A Price / Cash FlowN/A Book Value$33.24 per share Price / Book9.92Miscellaneous Outstanding Shares38,148,000Free Float33,157,000Market Cap$12.58 billion OptionableOptionable Beta1.18 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:KRTX) was last updated on 8/2/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA New Gold Era Is Coming - Here's How to Help Protect Your Retirement NowWashington insiders are quietly talking about a coordinated move to revalue gold—and with the national debt ap...Preserve Gold | SponsoredAI is not overTesla and Alphabet just tumbled, and many investors concluded AI is over. It isn't - the easy AI trade may be....The Oxford Club | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karuna Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
